KNSA - NASDAQ

Kiniksa Pharmaceuticals, Ltd.

KNSA·NASDAQ

$47.85

+0.073%

HealthcareBiotechnology

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.60B

EPS0.8000

P/E Ratio59.81

Earnings Date07/28/2026

763.63M

Assets

32%

3Y+66.0%

5Y+119.0%

10Y+1252.0%

196.03M

Total Liabilities

38%

3Y+209.0%

5Y+422.0%

10Y+138.0%

567.61M

Total Equity

29%

3Y+43.0%

5Y+82.0%

10Y-2306.0%

Kiniksa Pharmaceuticals, Ltd. Funding & Solvency Profile

KNSA · NASDAQ

Current Assets

Cash & Cash Equivalents165.60M

Net Receivables15.59M

Inventory54.90M

Other Current Assets42.61M

Total Current Assets527 M

Non-Current Assets

Property, Plant & Equipment11.75M

Goodwill & Intangible Assets15.25M

Long-Term Investments0.00

Other Non-Current Assets11.31M

Total Non-Current Assets23 M

Total Assets

763.63M

Financial Health Analysis

Current Ratio

3.79x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.35x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

388 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

69% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Kiniksa Pharmaceuticals, Ltd. Balance Sheet

KNSA • NASDAQ

Kiniksa Pharmaceuticals, Ltd. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	165.6M	183.6M	108M	122.7M	122.5M	114M	46.9M	307.3M	45.6M	56M
Short-Term Investments	248.5M	60M	98.4M	67.9M	59.7M	209.4M	186.5M	0.0	0.0	0.0
Cash & Short-Term Investments	414.1M	243.6M	206.4M	190.6M	182.2M	323.5M	233.4M	307.3M	45.6M	56M
Net Receivables	15.6M	41.7M	21.3M	20.3M	4M	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	15.6M	41.7M	21.3M	12.7M	4M	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	7.7M	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	54.9M	26.4M	31.1M	21.6M	3.7M	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	6.6M	9.6M	8.2M	6.4M	1.4M	259K
Other Current Assets	42.6M	20.1M	17.5M	10.5M	0.0	210K	0.0	6.4M	105K	105K
Total Current Assets	527.2M	331.8M	276.3M	243.1M	196.4M	333.2M	241.6M	313.8M	47.1M	56.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	11.8M	11M	12.7M	7M	8.4M	10.6M	8.3M	6.4M	125K	84K
Intangible Assets	15.3M	16.3M	17.3M	18.3M	19.3M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	15.3M	16.3M	17.3M	18.3M	19.3M	0.0	0.0	-210K	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	210K	0.0	0.0
Tax Assets	198.1M	211.2M	219.3M	185.5M	0.0	10K	4.4M	1.2M	238K	41K
Other Non-Current Assets	11.3M	10.3M	827K	5.8M	8.7M	5.6M	210K	643K	25K	8K
Total Non-Current Assets	236.5M	248.8M	250M	216.6M	36.4M	16.2M	12.9M	8.2M	388K	133K
Total Assets	763.6M	580.6M	526.3M	459.7M	232.8M	349.5M	254.5M	322M	47.5M	56.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2M	2M	8.2M	7.9M	1.9M	503K	5.7M	10.9M	1.2M	212K
Accounts Payable	2M	2M	8.2M	7.9M	1.9M	503K	5.7M	10.9M	1.2M	212K
Accrued Expenses	0.0	0.0	16M	18.9M	38M	21.5M	13.3M	5.7M	1.6M	986K
Short Term Debt	3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	2M	2.3M	3.3M	3.4M	2.1M	1.7M	0.0	0.0	0.0
Deferred Revenue	31.8M	0.0	307K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	102.4M	96.6M	36.9M	17M	1.5M	7.7M	7.1M	26M	14.6M	1.1M
Total Current Liabilities	139.2M	100.6M	63.7M	47.1M	44.8M	31.8M	27.8M	42.6M	17.4M	2.3M
NON-CURRENT LIABILITIES
Long Term Debt	6.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	31.8M	12M	12M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	0.0
Other Non-Current Liabilities	50.3M	1.8M	1.9M	1.8M	270K	805K	326K	144K	119.8M	79.9M
Total Non-Current Liabilities	56.8M	41.5M	23.8M	16.5M	2.9M	5.7M	1.3M	144K	119.8M	79.9M
Capital Lease Obligations	0.0	9.9M	12.3M	5.9M	6.1M	7M	2.7M	0.0	0.0	0.0
Total Liabilities	196M	142.1M	87.5M	63.5M	47.8M	37.5M	29.1M	42.7M	137.2M	82.2M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	119.8M	79.9M
Common Stock	21K	20K	20K	19K	18K	18K	15K	13K	1K	1K
Additional Paid-In Capital	1B	959.7M	916.8M	888.1M	860.5M	829.4M	581.5M	473.5M	1.3M	392K
Retained Earnings	-462.1M	-521.1M	-478M	-492M	-675.4M	-517.5M	-356.1M	-194.2M	-91M	-26.1M
Accumulated Other Comprehensive Income/Loss	-25K	-163K	6K	44K	-66K	-34K	33K	-4K	-52K	-24K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	52K	24K
Total Stockholders' Equity	567.6M	438.4M	438.8M	396.1M	185M	311.9M	225.4M	-194.2M	-89.7M	-25.7M
Total Equity	567.6M	438.4M	438.8M	396.1M	185M	311.9M	225.4M	-194.2M	-89.7M	-25.7M
SUMMARY
Total Liabilities & Equity	763.6M	580.6M	526.3M	459.7M	232.8M	349.5M	254.5M	-151.5M	47.5M	56.5M
Total Investments	248.5M	60M	98.4M	67.9M	59.7M	209.4M	186.5M	210K	0.0	0.0
Total Debt	9.5M	9.9M	12.3M	5.9M	6.1M	7M	2.7M	0.0	0.0	0.0
Net Debt	-156.1M	-173.7M	-95.7M	-116.8M	-116.4M	-107.1M	-44.3M	-307.3M	-45.6M	-56M
Shares Outstanding	75,171,467	75,171,467	75,171,467	75,171,467	75,171,467	75,171,467	75,171,467	75,171,467	75,171,467	75,171,467

SEC Filings

KNSA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 26, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	April 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 28, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 16, 2026	May 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 14, 2026	January 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing

Showing 1 to 10 of 131 filings

Related Guides

Blog Categories

Continue your KNSA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.